<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: Initial results from the EMPRISE real-world study of empagliflozin compared with DPP-4 inhibitors presented at ACC.19 and AMCP 2019	</title>
	<atom:link href="https://www.novumpr.nl/2019/03/28/initial-results-from-the-emprise-real-world-study-of-empagliflozin-compared-with-dpp-4-inhibitors-presented-at-acc-19-and-amcp-2019/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.novumpr.nl/2019/03/28/initial-results-from-the-emprise-real-world-study-of-empagliflozin-compared-with-dpp-4-inhibitors-presented-at-acc-19-and-amcp-2019/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=initial-results-from-the-emprise-real-world-study-of-empagliflozin-compared-with-dpp-4-inhibitors-presented-at-acc-19-and-amcp-2019</link>
	<description>NovumPR press releases</description>
	<lastBuildDate>Thu, 28 Mar 2019 09:17:26 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.8.2</generator>
</channel>
</rss>
